title: Tumor assessment criteria in phase I trials: beyond RECIST.
authors.forename: Antonin
authors.initials: A
authors.lastname: Levy
authors.forename: Antoine
authors.initials: A
authors.lastname: Hollebecque
authors.forename: Charles
authors.initials: C
authors.lastname: Ferté
authors.forename: Serge
authors.initials: S
authors.lastname: Koscielny
authors.forename: Mariana
authors.initials: M
authors.lastname: Fernandez
authors.forename: Jean-Charles
authors.initials: JC
authors.lastname: Soria
authors.forename: Christophe
authors.initials: C
authors.lastname: Massard
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000401:mortality* / Q000473:pathology*; D047368:Tumor Burden / Q000187:drug effects*
chemical_list: D000970:Antineoplastic Agents